Literature DB >> 17875570

Association between 25-hydroxyvitamin D deficiency and cardiovascular disease in type 2 diabetic patients with mild kidney dysfunction.

Michel Chonchol1, Massimo Cigolini, Giovanni Targher.   

Abstract

BACKGROUND: A potentially modifiable and underestimated risk factor for cardiovascular disease (CVD) in subjects with kidney dysfunction is 25-hydroxyvitamin D deficiency, although the relationship between inadequate vitamin D status and manifest CVD in type 2 diabetic subjects with mild kidney impairment has not been extensively examined.
METHODS: We evaluated the relationship between serum 25-hydroxyvitamin D concentrations, baseline kidney function (estimated using the modification of diet in renal disease equation) and manifest CVD (myocardial infarction, angina, ischaemic stroke, coronary revascularization or carotid endarterectomy) among 462 consecutive patients with type 2 diabetes.
RESULTS: In the whole population, the mean age was 62+/-7 years, 64% were men, 76.3% had hypertension and the mean estimated glomerular filtration rate (GFR) was 94+/-33 ml/min/1.73 m(2). Kidney function was strongly and inversely associated with CVD. In multivariate logistic regression analysis, there was an inverse association between serum 25-hydroxyvitamin D concentrations and prevalent CVD [odds ratio 0.95 (95% CI 0.92-0.98; P=0.001)] in the whole population independent of baseline kidney function and other known risk factors. Additionally, the association between serum 25-hydroxyvitamin concentrations and CVD [odds ratio 0.97 (95% CI 0.94-0.99; P=0.045)] remained statistically significant in participants in the lowest estimated GFR tertile after adjustment for potential confounders.
CONCLUSIONS: Decreased 25-hydroxyvitamin D concentrations are independently associated with prevalent CVD in type 2 diabetic patients with mild kidney dysfunction.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17875570     DOI: 10.1093/ndt/gfm537

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  18 in total

1.  Hypovitaminosis D: a novel risk factor for coronary heart disease in type 2 diabetes?

Authors:  Giovanna Muscogiuri; Vincenzo Nuzzo; Adriano Gatti; Alfonso Zuccoli; Silvia Savastano; Carolina Di Somma; Rosario Pivonello; Francesco Orio; Annamaria Colao
Journal:  Endocrine       Date:  2015-05-01       Impact factor: 3.633

2.  Effect of paricalcitol on endothelial function and inflammation in type 2 diabetes and chronic kidney disease.

Authors:  Tina K Thethi; Muhammad A Bajwa; Husam Ghanim; Chanhee Jo; Monica Weir; Allison B Goldfine; Guillermo Umpierrez; Cyrus Desouza; Paresh Dandona; Ying Fang-Hollingsworth; Vasudevan Raghavan; Vivian A Fonseca
Journal:  J Diabetes Complications       Date:  2015-01-13       Impact factor: 2.852

3.  Vitamin D receptor agonist doxercalciferol modulates dietary fat-induced renal disease and renal lipid metabolism.

Authors:  Xiaoxin X Wang; Tao Jiang; Yan Shen; Hannah Santamaria; Nathaniel Solis; Cynthia Arbeeny; Moshe Levi
Journal:  Am J Physiol Renal Physiol       Date:  2011-01-05

4.  Physical activity, sedentary behavior, and vitamin D metabolites.

Authors:  Elizabeth A Hibler; Christine L Sardo Molmenti; Qi Dai; Lindsay N Kohler; Shaneda Warren Anderson; Peter W Jurutka; Elizabeth T Jacobs
Journal:  Bone       Date:  2015-11-24       Impact factor: 4.398

5.  1,25(OH)2 vitamin d inhibits foam cell formation and suppresses macrophage cholesterol uptake in patients with type 2 diabetes mellitus.

Authors:  Jisu Oh; Sherry Weng; Shaili K Felton; Sweety Bhandare; Amy Riek; Boyd Butler; Brandon M Proctor; Marvin Petty; Zhouji Chen; Kenneth B Schechtman; Leon Bernal-Mizrachi; Carlos Bernal-Mizrachi
Journal:  Circulation       Date:  2009-08-10       Impact factor: 29.690

Review 6.  Does vitamin D protect against cardiovascular disease?

Authors:  Shari S Bassuk; Joann E Manson
Journal:  J Cardiovasc Transl Res       Date:  2009-07-17       Impact factor: 4.132

7.  Vitamin D receptor agonist supplementation and suppression of inflammation may have advantage for all-cause mortality in hemodialysis patients.

Authors:  Tetsuya Ogawa; Ai Kyono; Masayo Sato; Himiko Sugimoto; Kuniaki Otsuka; Kosaku Nitta
Journal:  Clin Exp Nephrol       Date:  2012-03-29       Impact factor: 2.801

8.  Oral active vitamin d treatment and mortality in maintenance hemodialysis patients.

Authors:  Shukun Wu; Junru Wang; Fang Wang; Li Wang
Journal:  Cardiorenal Med       Date:  2014-10-22       Impact factor: 2.041

9.  Assessment of 24,25(OH)2D levels does not support FGF23-mediated catabolism of vitamin D metabolites.

Authors:  Bing Dai; Valentin David; Hala M Alshayeb; Arif Showkat; Geeta Gyamlani; Ronald L Horst; Barry M Wall; L Darryl Quarles
Journal:  Kidney Int       Date:  2012-06-27       Impact factor: 10.612

10.  Effect of Vitamin D Supplementation, Omega-3 Fatty Acid Supplementation, or a Strength-Training Exercise Program on Clinical Outcomes in Older Adults: The DO-HEALTH Randomized Clinical Trial.

Authors:  Heike A Bischoff-Ferrari; Bruno Vellas; René Rizzoli; Reto W Kressig; José A P da Silva; Michael Blauth; David T Felson; Eugene V McCloskey; Bernhard Watzl; Lorenz C Hofbauer; Dieter Felsenberg; Walter C Willett; Bess Dawson-Hughes; JoAnn E Manson; Uwe Siebert; Robert Theiler; Hannes B Staehelin; Caroline de Godoi Rezende Costa Molino; Patricia O Chocano-Bedoya; Lauren A Abderhalden; Andreas Egli; John A Kanis; Endel J Orav
Journal:  JAMA       Date:  2020-11-10       Impact factor: 56.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.